107 related articles for article (PubMed ID: 21982019)
1. HNF1B polymorphism associated with development of prostate cancer in Korean patients.
Kim HJ; Bae JS; Lee J; Chang IH; Kim KD; Shin HD; Han JH; Lee SY; Kim W; Myung SC
Urology; 2011 Oct; 78(4):969.e1-6. PubMed ID: 21982019
[TBL] [Abstract][Full Text] [Related]
2. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
[TBL] [Abstract][Full Text] [Related]
3. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
Sun J; Wiklund F; Zheng SL; Chang B; Bälter K; Li L; Johansson JE; Li G; Adami HO; Liu W; Tolin A; Turner AR; Meyers DA; Isaacs WB; Xu J; Grönberg H
J Natl Cancer Inst; 2005 Apr; 97(7):525-32. PubMed ID: 15812078
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
[TBL] [Abstract][Full Text] [Related]
5. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer.
Lindmark F; Zheng SL; Wiklund F; Bensen J; Bälter KA; Chang B; Hedelin M; Clark J; Stattin P; Meyers DA; Adami HO; Isaacs W; Grönberg H; Xu J
J Natl Cancer Inst; 2004 Aug; 96(16):1248-54. PubMed ID: 15316060
[TBL] [Abstract][Full Text] [Related]
6. Single nucleotide polymorphisms in DKK3 gene are associated with prostate cancer risk and progression.
Kim MS; Lee HN; Kim HJ; Myung SC
Int Braz J Urol; 2015; 41(5):869-97. PubMed ID: 26689513
[TBL] [Abstract][Full Text] [Related]
7. Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men.
Park K; Kim JH; Jeon HG; Byun SS; Lee E
Urology; 2010 Jun; 75(6):1516.e1-7. PubMed ID: 20350746
[TBL] [Abstract][Full Text] [Related]
8. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
Dos Reis ST; Pontes J; Villanova FE; Borra PM; Antunes AA; Dall'oglio MF; Srougi M; Leite KR
J Urol; 2009 May; 181(5):2320-5. PubMed ID: 19303106
[TBL] [Abstract][Full Text] [Related]
10. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer.
Chen YC; Giovannucci E; Lazarus R; Kraft P; Ketkar S; Hunter DJ
Cancer Res; 2005 Dec; 65(24):11771-8. PubMed ID: 16357190
[TBL] [Abstract][Full Text] [Related]
11. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
[TBL] [Abstract][Full Text] [Related]
12. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
[TBL] [Abstract][Full Text] [Related]
13. Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness.
Cicek MS; Nock NL; Li L; Conti DV; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1331-6. PubMed ID: 15298954
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D receptor genotypes/haplotypes and prostate cancer risk.
Cicek MS; Liu X; Schumacher FR; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2549-52. PubMed ID: 17164384
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the association between the HNF1B rs4430796 (A>G) polymorphism and risk of prostate cancer based on case-control studies.
Zhao Y; Liang J; Qi JG; Yang N; Wu G; Lin YL; Cao JY; Wang Q; Wang QC
Genet Mol Res; 2015 Jul; 14(3):7426-35. PubMed ID: 26214421
[TBL] [Abstract][Full Text] [Related]
16. Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer.
Hedelin M; Bälter KA; Chang ET; Bellocco R; Klint A; Johansson JE; Wiklund F; Thellenberg-Karlsson C; Adami HO; Grönberg H
Prostate; 2006 Oct; 66(14):1512-20. PubMed ID: 16921512
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk.
Singal R; Ferdinand L; Das PM; Reis IM; Schlesselman JJ
Int J Oncol; 2004 Nov; 25(5):1465-71. PubMed ID: 15492840
[TBL] [Abstract][Full Text] [Related]
18. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
Gudmundsson J; Sulem P; Steinthorsdottir V; Bergthorsson JT; Thorleifsson G; Manolescu A; Rafnar T; Gudbjartsson D; Agnarsson BA; Baker A; Sigurdsson A; Benediktsdottir KR; Jakobsdottir M; Blondal T; Stacey SN; Helgason A; Gunnarsdottir S; Olafsdottir A; Kristinsson KT; Birgisdottir B; Ghosh S; Thorlacius S; Magnusdottir D; Stefansdottir G; Kristjansson K; Bagger Y; Wilensky RL; Reilly MP; Morris AD; Kimber CH; Adeyemo A; Chen Y; Zhou J; So WY; Tong PC; Ng MC; Hansen T; Andersen G; Borch-Johnsen K; Jorgensen T; Tres A; Fuertes F; Ruiz-Echarri M; Asin L; Saez B; van Boven E; Klaver S; Swinkels DW; Aben KK; Graif T; Cashy J; Suarez BK; van Vierssen Trip O; Frigge ML; Ober C; Hofker MH; Wijmenga C; Christiansen C; Rader DJ; Palmer CN; Rotimi C; Chan JC; Pedersen O; Sigurdsson G; Benediktsson R; Jonsson E; Einarsson GV; Mayordomo JI; Catalona WJ; Kiemeney LA; Barkardottir RB; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
Nat Genet; 2007 Aug; 39(8):977-83. PubMed ID: 17603485
[TBL] [Abstract][Full Text] [Related]
19. P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype.
Rogler A; Rogenhofer M; Borchardt A; Lunz JC; Knoell A; Hofstaedter F; Tannapfel A; Wieland W; Hartmann A; Stoehr R
Pathobiology; 2011; 78(4):193-200. PubMed ID: 21778786
[TBL] [Abstract][Full Text] [Related]
20. Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease.
Bao BY; Pao JB; Lin VC; Huang CN; Chang TY; Lan YH; Lu TL; Lee HZ; Chen LM; Ting WC; Hsieh CJ; Huang SP
Clin Chim Acta; 2010 Sep; 411(17-18):1232-7. PubMed ID: 20450899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
